CorMedix Inc. — Director's Dealing 2010

Apr 1, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2010-03-30

Reporting Person: ELLISON RUSSELL H (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-03-30	Common Stock, $0.001 par value per share	P	160000	—	Acquired	160000	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-03-30	Stock option (right to buy)	$3.1250	A	20000	Acquired	2020-03-30	Common Stock, $0.001 par value per share (20000)	Direct
2010-03-30	Warrants issued as a part of Units	$3.4375	P	80000	Acquired	2015-03-24	Common Stock, $0.001 par value (80000)	Indirect

Footnotes

F1: These securities were issued as a part of 80,000 Units purchased by Global Paramount BioFund, LP (the ''Fund'') directly from the underwriters in the Company's initial
public offering, which closed on March 30, 2010. The Units were purchased at $6.50 per Unit, the initial public offering price. Each Unit consists of two shares of
common stock and a warrant to purchase one share of common stock.

F2: The Fund is the direct owner of the subject securities. Mr. Ellison is a managing member of Global BioFund GP, LLC, the general partner of the Fund, and a portfolio
manager of Global Bio Asset Management, LP, the investment manager of the Fund. Mr. Ellison disclaims beneficial ownership of such securities, except to the extent
of his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Ellison is the beneficial owner of the securities for purposes of Section
16 of the Securities Exchange Act of 1934, as amended or for any other purpose.

F3: These options vest as follows: 1/3 on March 30, 2010; an additional 1/3 on March 30, 2011; and the remaining 1/3 on March 30, 2012.

F4: These warrants will become exercisable upon the earlier to occur of the expiration of the underwriters' over allotment option with respect to the Company's initial public offering, or the exercise in full of such over allotment option.